Emicizumab
Von Willebrand Disease, Type 3
Bleeding and Clotting Disorders Institute Peoria, Illinoismonoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Von Willebrand Disease, Type 3 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Von Willebrand Factor Fondazione Angelo Bianchi Bonomi | D |
Same molecule, other indications
Emicizumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →